Join Us

Over the last few months, the FTC has continued to expand its scrutiny of pharmaceutical and biotech deals (both acquisitions and collaboration/licensing transactions) including looking more closely at overlaps involving early-stage assets and the impact deals have on innovation, rebate practices, and future competition. Last May, the FTC challenged Amgen’s acquisition of Horizon Therapeutics under a novel rebate bundling theory before settling with the parties mid-litigation. In December, in a major departure from its historical focus on overlaps between marketed and/or late-stage products, the FTC challenged a licensing deal between Sanofi and Maze Therapeutics for an early-stage therapy in development to treat a rare genetic disorder. The Agency continues to expand the theories of harm in its arsenal to challenge bio-pharma deals — are you ready?

Join experts from Fenwick's Antitrust and Life Sciences practices as they offer valuable insights into the current landscape and discuss how companies can navigate the risks when planning pharmaceutical and biotech transactions.

The conversation will run about an hour — stick around afterward for a networking happy hour with panelists and fellow guests!

If you have any questions, please contact Samantha Schmidig or +1 650-335-6075.

Speakers

Agenda